S&P 500   3,340.88 (-0.96%)
DOW   29,008.43 (-0.72%)
QQQ   231.07 (-1.58%)
AAPL   314.93 (-1.68%)
FB   210.59 (-1.86%)
MSFT   179.53 (-2.65%)
GOOGL   1,499.45 (-1.16%)
AMZN   2,109.43 (-2.03%)
CGC   22.01 (-1.34%)
NVDA   295.16 (-4.39%)
BABA   213.82 (-1.94%)
MU   56.76 (-3.80%)
GE   12.31 (-1.76%)
TSLA   888.54 (-1.21%)
AMD   53.93 (-5.85%)
T   38.45 (-0.41%)
ACB   1.66 (-1.19%)
F   7.92 (-1.37%)
NFLX   381.65 (-1.13%)
PRI   132.90 (-2.57%)
DIS   139.38 (-0.71%)
GILD   69.28 (+3.40%)
S&P 500   3,340.88 (-0.96%)
DOW   29,008.43 (-0.72%)
QQQ   231.07 (-1.58%)
AAPL   314.93 (-1.68%)
FB   210.59 (-1.86%)
MSFT   179.53 (-2.65%)
GOOGL   1,499.45 (-1.16%)
AMZN   2,109.43 (-2.03%)
CGC   22.01 (-1.34%)
NVDA   295.16 (-4.39%)
BABA   213.82 (-1.94%)
MU   56.76 (-3.80%)
GE   12.31 (-1.76%)
TSLA   888.54 (-1.21%)
AMD   53.93 (-5.85%)
T   38.45 (-0.41%)
ACB   1.66 (-1.19%)
F   7.92 (-1.37%)
NFLX   381.65 (-1.13%)
PRI   132.90 (-2.57%)
DIS   139.38 (-0.71%)
GILD   69.28 (+3.40%)
S&P 500   3,340.88 (-0.96%)
DOW   29,008.43 (-0.72%)
QQQ   231.07 (-1.58%)
AAPL   314.93 (-1.68%)
FB   210.59 (-1.86%)
MSFT   179.53 (-2.65%)
GOOGL   1,499.45 (-1.16%)
AMZN   2,109.43 (-2.03%)
CGC   22.01 (-1.34%)
NVDA   295.16 (-4.39%)
BABA   213.82 (-1.94%)
MU   56.76 (-3.80%)
GE   12.31 (-1.76%)
TSLA   888.54 (-1.21%)
AMD   53.93 (-5.85%)
T   38.45 (-0.41%)
ACB   1.66 (-1.19%)
F   7.92 (-1.37%)
NFLX   381.65 (-1.13%)
PRI   132.90 (-2.57%)
DIS   139.38 (-0.71%)
GILD   69.28 (+3.40%)
S&P 500   3,340.88 (-0.96%)
DOW   29,008.43 (-0.72%)
QQQ   231.07 (-1.58%)
AAPL   314.93 (-1.68%)
FB   210.59 (-1.86%)
MSFT   179.53 (-2.65%)
GOOGL   1,499.45 (-1.16%)
AMZN   2,109.43 (-2.03%)
CGC   22.01 (-1.34%)
NVDA   295.16 (-4.39%)
BABA   213.82 (-1.94%)
MU   56.76 (-3.80%)
GE   12.31 (-1.76%)
TSLA   888.54 (-1.21%)
AMD   53.93 (-5.85%)
T   38.45 (-0.41%)
ACB   1.66 (-1.19%)
F   7.92 (-1.37%)
NFLX   381.65 (-1.13%)
PRI   132.90 (-2.57%)
DIS   139.38 (-0.71%)
GILD   69.28 (+3.40%)
Log in

NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

$6.36
-0.17 (-2.60 %)
(As of 02/21/2020 01:14 PM ET)
Today's Range
$6.21
Now: $6.37
$6.53
50-Day Range
$3.83
MA: $6.05
$7.26
52-Week Range
$3.24
Now: $6.37
$9.25
Volume194,388 shs
Average Volume662,052 shs
Market Capitalization$234.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.07 million
Book Value$0.81 per share

Profitability

Net Income$-94,350,000.00
Net Margins-1,553.29%

Miscellaneous

Employees130
Market Cap$234.23 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.


Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.03. The business earned $1.18 million during the quarter, compared to the consensus estimate of $2.92 million. Kala Pharmaceuticals had a negative return on equity of 173.83% and a negative net margin of 1,553.29%. View Kala Pharmaceuticals' Earnings History.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Kala Pharmaceuticals.

What price target have analysts set for KALA?

5 analysts have issued 1-year price targets for Kala Pharmaceuticals' stock. Their forecasts range from $6.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $18.20 in the next year. This suggests a possible upside of 185.9% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

What is the consensus analysts' recommendation for Kala Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Has Kala Pharmaceuticals been receiving favorable news coverage?

Media coverage about KALA stock has trended positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Kala Pharmaceuticals.

Are investors shorting Kala Pharmaceuticals?

Kala Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,240,000 shares, an increase of 11.5% from the January 15th total of 4,700,000 shares. Based on an average trading volume of 545,600 shares, the short-interest ratio is currently 9.6 days. Currently, 19.4% of the shares of the company are short sold. View Kala Pharmaceuticals' Current Options Chain.

Who are some of Kala Pharmaceuticals' key competitors?

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), Amarin (AMRN), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX) and REDHILL BIOPHAR/S (RDHL).

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)
  • Mr. Todd Bazemore, Chief Operating Officer (Age 49)
  • Dr. Kim Brazzell, Chief Medical Officer (Age 66)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 44)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Banco Bilbao Vizcaya Argentaria S.A. (4.06%), Sofinnova Investments Inc. (1.92%), Polaris Venture Management Co. V L.L.C. (1.64%), Alyeska Investment Group L.P. (1.27%), State Street Corp (1.05%) and Geode Capital Management LLC (0.92%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

Which major investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Bank of America Corp DE, Alambic Investment Management L.P. and Group One Trading L.P.. View Insider Buying and Selling for Kala Pharmaceuticals.

Which major investors are buying Kala Pharmaceuticals stock?

KALA stock was bought by a variety of institutional investors in the last quarter, including Banco Bilbao Vizcaya Argentaria S.A., Sofinnova Investments Inc., Wedbush Securities Inc., State Street Corp, Alyeska Investment Group L.P., Geode Capital Management LLC, Virtu Financial LLC and UBS Group AG. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $6.37.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $234.23 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]


MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel